Defeitos na expressão de cadeia zeta (ζ) em um grupo de pacientes com Lúpus, Esclerodermia e artrite de início tardio, Colômbia 2014

DOI:  https://doi.org/10.12804/revsalud12.03.2014.01

Barra lateral de artigos

PDF (Español (España))

Publicado: sept. 26, 2014
Edição: v. 12 n. 3 (2014)
Seção Artículo de investigación clínica o experimental


Palavras-chave: ζ Chain Corticosteroids , T-Cells , Splicing , Lupus Erythematosus (SLE) , T-Cell Receptor (TCR) , IgG Fraction Crystallizable (Fcγ) , Cytokines , Autoimmunity. Corticoides cadena ζ , celulas T , splicing , lupus eritematoso sistémico (LES) , receptor de la célula T (TCR) , fracción cristalizable de IgG(Fcγ) , citoquinas , autoinmunidad. Corticoides Cadeia ζ , celulas T , Splicing , Lupus Eritematoso Sistemico (LES) , Receptor da celula T (TCR) , Fracao cristalizavel de IgG (Fcg) , citocinas , autoimunidade.

Conteúdo do artigo principal

Autores

Heber Siachoque-Montañez
Milcíades Ibáñez-Pinilla
Antonio Iglesias-Gamarra
Resumo

Introdução: O Lupus Eritematoso Sistemico (LES), Esclerodermia e Artite de inicio tardio sao doencas inflamatorias autoimunes caracterizadas por producao de autoanticorpos e presenca de celulas T anormais as quais geram resposta imune defeituosa. A expressao anormal de moléculas chave em sinalizacao e a funcao defeituosa dos linfocitos T cumprem um papel significativo na patogenese da doenca autoimune. As celulas T mostram numerosas anormalidades na sinalizacao do Complexo Receptor de celula T cadeia zeta (TCRζ)1, estas aberracoes resultam na alteracao da expressao de citocinas e alguns eventos bioquimicos envolvidos na expressao de moleculas de superficie. Os defeitos no complexo TCRζ podem estar associados ao uso de corticoides, utilizados em pacientes com doenca autoimune devido a seu potente atividade auto-inflamatoria e propiedades imunossupressoras. Os corticoides sinteticos como a dexametasona inibem a atividade transcricional de alguns fatores como NFkB e AP-1 os quais regulam a sintese de algumas citocinas e poderiam estar envolvidas na sintese de TCRζ2, 3. Objetivos: Avaliar a associacao dos defeitos da expressao de cadeia zeta (ζ), em celulas T de pacientes com doenca autoimune sem tratamento com corticoides. Os defeitos na expressao defeituosa de zeta, proteina associada ao receptor TCR altera a ativacao normal do linfocito T. Materiais e métodos: Estudo analitico de casos e controles, com uma relacao 1:1 (13:13). Os casos foram pacientes com doenca autoimune ativa (6 pacientes com LES, 5 pacientes com esclerodermia e 2 pacientes com artrite de inicio tardio), e que nao tenham iniciado tratamento com corticoides e os controles foram pacientes sem diagnostico de doenca autoimune. O diagnostico se fez atraves dos criterios estabelecidos pelo Colegio Americano de Reumatologia para pacientes com LES, esclerodermia e artrite de inicio tardio. Se realizou venopuncao extraindo 10mls de sangue total, se extraiu RNA total e se fez RT PCR, se amplificou utilizando um jogo de primers que flanqueiam uma regiao de 138 pares de bases que envolviam os exoes 2, 3 e 4 de cadeia ζ. Resultados: Nos valores de amplificacao de cadeia Z se encontraram diferencas significativas em pacientes com doenca autoimune (0.8214}0.1787, med=0.7368) comparada com o grupo controle (0.9225}0.1272, med=0.9830) (p=0.045, Teste nao parametrico, exato de Mann Whitney) Conclusão: A expressao de cadeia Z encontrou-se diminuida em celulas T de pacientes com doenca autoimune, sem uso de corticoides, a diminuicao ou uma falta de expressao da cadeia Z pode causar alteracoes na resposta imune.

Biografia do Autor

Heber Siachoque-Montañez

Coordinador de la Unidad de Inmunología, Facultad de Medicina, Universidad del Rosario, Bogotá D. C., Colombia.

Milcíades Ibáñez-Pinilla

Profesor titular, Facultad de Medicina, Universidad Nacional de Colombia.

Antonio Iglesias-Gamarra

Profesor titular, Facultad de Medicina, Universidad Nacional de Colombia.
Como Citar
Siachoque-Montañez, H., Ibáñez-Pinilla, M., & Iglesias-Gamarra, A. (2014). Defeitos na expressão de cadeia zeta (ζ) em um grupo de pacientes com Lúpus, Esclerodermia e artrite de início tardio, Colômbia 2014. Revista Ciencias De La Salud, 12(3), 303–318. https://doi.org/10.12804/revsalud12.03.2014.01
Referências

Juang CM, Hung CF,Yeh JY, Horng HC,Twu NF, Cheng MH, et al. Regulatory T cells: potential target

in anticancer immunotherapy. Taiwan J Obstet Gynecol. 2007; 46(3):215-21.

Akbari O, Stock P, DeKruyff R, Umetsu D. Role of regulatory T cells in allergy and asthma. Curr Opin

Immunol. 2003;15(6):627-33.

Siachoque H, Rondón F, Restrepo JF, Pérez R, Iglesias A. Defectos en la síntesis de cadena ζ en el linfocito

T, generando señales intracelulares equivocadas, responsables de lupus eritematoso sistémico.

Rev Colomb Reumatol. 2010; 17(4):219-30.

Tsokos CG, Liossis SN. Immune cell signaling defects in lupus: activation, anergy and death. Immunol.

Today. 1999; 20:119-24.

Jensen JP, HouD, Ramsburg M, Taylor A, Dean M, Weissman AM. Organization of the human T cell

receptor zeta/eta gene and its genetic linkage to the Fc gamma RII-Fc gamma RIII gene cluster. J Immunol.

; 148(8):2563-71.

Takeuchi T, TsuzakaK, Pang M, Amano K, Koide J, Abe T. TCR zeta chain lacking exon 7 in two patients

with systemic lupus erythematosus. IntImmunol.1998; 10(7):911-21.

Nambiar MP, Enyedy EJ, Fisher CU, Krishnan S, Warke VG, Guilliland WR, et al. Abnormal expression

of various molecular forms and distribution of T cell receptor zeta chain in patients with systemic

lupus erythematosus. Arthritis Rheum. 2002;46(1):163-74.

Vassilopoulos D, Kovacs B, Tsokos GC. TCR/CD3complex-mediated signal transduction pathway in T

cells and T cell lines from patients with systemic lupus erythematosus. J Immunol.1995;155(4):2269-81.

Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, Delaney N, et al. Alterations in lipid raft

composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus.

JImmunol. 2004;172(12):7821-31.

Spies CM, Strehl C, Van der Goes MC, Bijlsma J, Buttgereit F. Glucocorticoids. Best Practice & Research

Clinical Rheumatology. 2011;25:891-900.

Hoffman GS. Immunosuppressive therapy for autoimmune diseases. Ann Allergy. 1993;70(4):263-74.

Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids,

recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2-13.

Clark AR. Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol.

;275(1-2):79-97.

Alessandri AL, Sousa LP, Lucas CD, Rossi AG, PinhoV. Teixeira M. Resolution of inflammation: mechanisms

and opportunity for drug development. Pharmacol Ther. 2013;139(2):189-212.

Nambiar MP, Enyedy EJ, Fisher CU, Warke VG, Juang Y, Tsokos GC. Dexamethasone modulates TCR

zeta chain expression and antigen receptor-mediated early signaling events in human T lymphocytes.

Cell Immunol. 2001;208(1):62-71.

Liberman AC, Druker J, Perone MJ, Arzt E. Glucocorticoids in the regulation of transcription factors

that control cytokine synthesis. Cytokine Growth Factor Rev 2007;18(1-2):45-56.

Flammer JR, Rogatsky I. Minireview: Glucocorticoids in autoimmunity: unexpected targets and

mechanisms. Mol Endocrinol. 2011;25(7):1075-86.

Fahey AJ, Robins RA, Kindle KB, Heery DM, Constantinescu CS. Effects of glucocorticoids on STAT4

activation in human T cells are stimulus-dependent. J Leukoc Biol. 2006;80(1):133-44.

Luther C, Adamopoulou E, Stoeckle C, Brucklacher-Waldert V, Rosenkranz D, Stoltze L, et al. Prednisolone

treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis

patients. J Immunol. 2009;183(2):841-8.

Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs Th-17 cell differentiation

by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967-74.

Flammer JR, Dobrovolna J, Kennedy MA, Chinenov Y, Glass CK, Ivashkiv LB, Rogatsky I. Type I interferon

signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol. 2010;30(19):4564-74.

Velten FW, Duperrier K, Bohlender J, Metharom P, Goerdt S. A gene signature of inhibitory MHC

receptors identifies a BDCA3(+) subset of IL-10-induced dendritic cells with reduced allostimulatory

capacity in vitro. Eur J Immunol. 2004;34(10):280011.

Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic

diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50(11):3408-17.

Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid

treatment of rheumatic diseases revisited. Arthritis Rheum. 1998;41:761-7.

Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of

signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent

mechanism. Br J Pharmacol. 2000;130(2):289-98.

Rhen T, Cidlowski JA. Anti-inflammatory action of glucocorticoids-new mechanisms for old drugs. N

Engl J Med. 2005;353(16):1711-23.

Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol.

;4(10):525-33.

Hoffman H, Rosengren S, Boyle DL, Cho JY, Nayar J, et al. Prevention of cold-associated acute inflammation

in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet.

;364:1779-1785.

Buttgereit F, Burmester GR, Straub RH, Seibel MJ, Zhou H. Exogenous and endogenous glucocorticoids

in rheumatic diseases. Arthritis Rheum. 2011;63(1):1-9.

Sakai A, Han J, Cato AC, Akira S, Li JD. Glucocorticoids synergize with IL-1beta to induce TLR2 expression

via MAP kinase phosphatase 1- dependent dual Inhibition of MAPK JNK and p38 in epithelial

cells. BMC Mol Biol. 2004;5:2

Beaulieu E, Morand EF. Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid

arthritis. Nat Rev Rheumatol. 2011;7(6):340-8.

Nambiar MP, Fisher CU, Warke VG, Krishnan S, Mitchell JP, Delaney N, et al. Reconstitution of deficient

T cell receptor chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2

production in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48(7):1948-55.

Tenbrock K, Juang T, Kyttaris VC, Tsokos GC. Altered signal transduction in SLE T cells. Rheumatology.

;46(10):1525-30.

Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, et al. Inhibition of Th1 immune

response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat-4 phosphorylation

in T lymphocytes. J Immunol. 2000;164:1768-74.

Li R, Yang W, Zhang J, Hirankarn N, Pan HF, Mok CC, et. al. Association of CD247 with systemic lupus

erythematosus in Asian populations. Lupus. 2012;21(1):75-83.

Yoshimoto K, Setoyama Y, Tsuzaka K, Abe T, Takeuchi T. Reduced Expression of TCR zeta is involved

in the abnormal production of cytokines by peripheral T cells of patients with systemic lupus erythematosus.

J Biomed-Biotechnol. 2010;10:1-6.

Irving BA, Chan AC, Weiss A. Functional characterization of a signal transducing motif present in the

T cell antigen receptor z chain. J Exp Med. 1993;177(4):1093-103.

Zenner G, Vorherr T, Mustelin T, Burn P. Differential and multiple binding of signal transducing

molecules to the ITAMs of the TCR zeta chain. J. Cell Biochem. 1996;63(1):94-103.

Wange RL, Samelson LE. Complex complexes: signalingat the TCR. Immunity. 1996;5(3):197-205.

Kersh EN, Shaw AS, Allen PM. Fidelity of T cell activation through multistep T cell receptor zeta

phosphorylation. Science. 1988;281(5376):572-5.

Kersh EN, Kersh GJ, Allen PM. Partially phosphorylated T cell receptor zeta molecules can inhibit T

cell activation. J Exp Med. 1999;190(11):1627-36.

Migliorati G, Bartoli A, Nocentini G, Ronchetti R, Moraca R, Riccardi C. Effect of dexamethasone on

T-cell receptor/CD3 expression. Mol Cell Biochem.1997;167(1-2):135-44.

Boumpas DT, Anastassiou ED, Older SA, Tsokos GC, Nelson DL, Balow JE. Dexamethasone inhibits

human interleukin 2 but not interleukin 2 receptor gene expression invitro at the level of nuclear

transcription. J. Clin. Invest. 1991;87(5):1739-47.

Barnes PJ, Adckock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol

Sci. 1993;14(12):436-41.

Giunchi L, Nocentini G, Ronchetti S, Bartoli A, Riccardi C, Migliorati G. TCR kappa, a new splicing

of the murine TCR zeta gene locus, is modulated by glucocorticoid treatment. Mol Cell Biochem.

;195(1-2):47-53.

Boldizsar F, Szabo M, Kvell K, Czompoly T, Talaber G, Bjorkan J, et al. ZAP-70 tyrosines 315 and 492

transmit non-genomic glucocorticoid (GC) effects in T cells. Mol Immunol. 2013;53(1-2):111-7.

Ronchetti S, Nocentini G, Giunchi L, Bartoli A, Moraca R, Riccardi C, Migliorati G. Short term dexamethasone

treatment modulates the expression of the murine TCR zeta gene locus. Cell Immunol.

;178(2):124-31.

Estatísticas de consulta

Downloads

Não há dados estatísticos.
Métricas de publicação

1518 1086




 

Los manuscritos postulados a la Revista Ciencias de la Salud deben ser originales e inéditos y no deben estar simultáneamente en proceso de publicación en otras revistas, compilaciones o cualquier otro medio de publicación. Los derechos de autor serán de la Universidad del Rosario. Cuando el autor quiera publicar el manuscrito en otra publicación, deberá pedir a la Editorial de la Universidad del Rosario los permisos correspondientes. De igual forma, cuando la Revista Ciencias de la Salud esté interesada en publicar artículos que ya han sido publicados en otras revistas, procederá a solicitar los permisos correspondientes en la editorial donde se realizó la primera publicación. 

Bajo una Creative Commons Attribution License los autores pueden compartir el trabajo con un reconocimiento de la autoría del trabajo y la publicación inicial en esta revista.

Artigos Semelhantes

1 2 3 4 5 6 > >> 

Você também pode iniciar uma pesquisa avançada por similaridade para este artigo.